The Uncertain Effect of Antimicrobial Therapy in the Treatment of Patients with Ischemic Colitis.
Jae Gon LeeJin-Hwa ParkDong Soo HanHang Lak LeeChan Hyuk ParkChang-Soo EunPublished in: Journal of clinical medicine (2020)
Although antimicrobial therapy is recommended for patients with moderate or severe ischemic colitis, its beneficial effects are unclear. In the present study, the role of antimicrobial therapy in the treatment of ischemic colitis was investigated. Patients with ischemic colitis were retrospectively identified between January 2004 and June 2019. The characteristics and outcomes of patients who received antibiotics (antibiotics group) and those who did not (no-antibiotics group) were compared. Clinical outcomes included death, surgery, and readmission within 30 days, fasting duration, and hospital stay. Data from 186 patients were analyzed; 122 patients were in the antibiotics group and 64 in the no-antibiotics group. Composite outcome of death, surgery, and readmission within 30 days occurred in 3.3% of patients in the antibiotics group and 3.1% of patients in the no-antibiotics group (p > 0.999). Fasting duration was not significantly different between the two groups (median days, 4.0 vs. 4.0, p = 0.253). However, hospital stays were longer in the antibiotics group than in the no-antibiotics group (median days, 9.0 vs. 7.0, p = 0.043). In patients with ischemic colitis, there was no statistically significant difference in the incidence of death, surgery, and readmission within 30 days between patients who received antibiotics and those who did not receive antibiotics.
Keyphrases
- newly diagnosed
- ejection fraction
- prognostic factors
- minimally invasive
- healthcare
- staphylococcus aureus
- metabolic syndrome
- emergency department
- machine learning
- coronary artery bypass
- bone marrow
- mass spectrometry
- high resolution
- coronary artery disease
- weight loss
- adipose tissue
- blood brain barrier
- brain injury
- patient reported
- cell therapy
- combination therapy
- data analysis